<code id='8AD2521A57'></code><style id='8AD2521A57'></style>
    • <acronym id='8AD2521A57'></acronym>
      <center id='8AD2521A57'><center id='8AD2521A57'><tfoot id='8AD2521A57'></tfoot></center><abbr id='8AD2521A57'><dir id='8AD2521A57'><tfoot id='8AD2521A57'></tfoot><noframes id='8AD2521A57'>

    • <optgroup id='8AD2521A57'><strike id='8AD2521A57'><sup id='8AD2521A57'></sup></strike><code id='8AD2521A57'></code></optgroup>
        1. <b id='8AD2521A57'><label id='8AD2521A57'><select id='8AD2521A57'><dt id='8AD2521A57'><span id='8AD2521A57'></span></dt></select></label></b><u id='8AD2521A57'></u>
          <i id='8AD2521A57'><strike id='8AD2521A57'><tt id='8AD2521A57'><pre id='8AD2521A57'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:fashion    Page View:4318

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In